[an error occurred while processing this directive]
口腔颌面外科杂志
 首页  |  期刊介绍  |  编 委 会  |  期刊订阅  |  投稿须知  |  联系我们  |  English
口腔颌面外科杂志  2017, Vol. 27 Issue (4): 229-    DOI: doi: 10.3969/j.issn.1005-4979.2017.04.001
专家论坛 最新目录 | 下期目录 | 过刊浏览 | 高级检索  |   
靶向治疗:口腔颌面-头颈部癌综合治疗的治疗选项
王中和
上海交通大学医学院附属第九人民医院口腔颌面头颈肿瘤科,上海   200011
Targeted Therapy: the Treatment Option of Combined Therapy for Oral-maxillofacial-head and Neck Cancer
Wang Zhonghe
Department of Oral and Maxillofacial-Head and Neck Oncology, Shanghai Ninth People’s Hospital, Shanghai Jiaotong University, Shanghai 200011, China
 全文: PDF (3436 KB)   HTML (1 KB)   输出: BibTeX | EndNote (RIS)      背景资料
摘要 靶向治疗通过基因检测选择阻断个体肿瘤细胞信号通路及特定基因靶点的药物,打击肿瘤细胞而不殃及正常细胞,疗效好且毒副作用小,是口腔颌面?鄄头颈部癌综合治疗的治疗选项。靶向治疗与放疗联用提高放射敏感性,对不能耐受同期放化疗的晚期、复发或伴有远处转移的患者也可单独应用。靶向治疗下降了头颈部癌复发或恶化风险,临床应用具有非常大的优势,正在成为综合治疗不可或缺的重要手段之一。
服务
把本文推荐给朋友
加入我的书架
加入引用管理器
E-mail Alert
RSS
作者相关文章
关键词 晚期口腔颌面-头颈部癌    靶向治疗    放射治疗    综合治疗     
Abstract: Targeting therapy using the drugs selected by genetic detection is to block specific gene target and signaling pathway in tumor cells. The therapy can kill the tumor cells and does not affect normal cells, and has good curative effect and less side effects, so it is considered to be a treatment option of combined therapy for oral and maxillofacial-head and neck cancer. Targeting therapy combined by radiation therapy improves radiosensitivity. For advanced patients with tumor recurrence, or with distant metastasis, who can't tolerate with concurrent radiation and chemotherapy, targeted therapy can be used alone. Targeting therapy can decline risks of recurrence or worsening, and has the very big advantage in clinical application, and is becoming one of the indispensable important means of the combined therapy in the patients with oral and maxillofacial-head and neck cancer.
Key wordsoral and maxillofacial-head and neck cancer        targeting therapy    radiation therapy    combined therapy   
通讯作者: 王中和(1943—),男,浙江省德清县人,教授,主任医师     E-mail: E-mail: fangliao9y@163.com
作者简介: 王中和(1943—),男,浙江省德清县人,教授,主任医师
引用本文:   
. 靶向治疗:口腔颌面-头颈部癌综合治疗的治疗选项[J]. 口腔颌面外科杂志, 2017, 27(4): 229-.
. Targeted Therapy: the Treatment Option of Combined Therapy for Oral-maxillofacial-head and Neck Cancer[J]. Journal of Oral and Maxillofacial Surgery, 2017, 27(4): 229-.
 
[1] 王中和. 口腔颌面-头颈肿瘤放射治疗学[M]. 上海: 上海世界图书出版公司, 2013.
[2] Prasasya RD, Tian D, Kreeger PK. Analysis of cancer signaling networks by systems biology to develop therapies[J]. Semin Cancer Biol, 2011, 21(3):200-206.
[3] Freidlin B, McShane LM, Polley MY, et al. Randomized phase II trial designs with biomarkers[J]. J Clin Oncol, 2012, 30(26): 3304-3309.
[4] Bonner JA, Harari PM, Giralt J, et al. Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck[J]. N Engl J Med, 2006, 354(6):567-578.
[5] Coca-Pelaz A, Rodrigo JP, Bradley PJ, et al. Adenoid cystic carcinoma of the head and neck--An update[J]. Oral Oncol, 2015, 51(7):652-661.
[6] Bonner JA, Harari PM, Giralt J, et al. Radiotherapy plus cetuximab for locoregionally advanced head and neck cancer: 5-year survival data from a phase 3 randomised trial, and relation between cetuximab-induced rash and survival[J]. Lancet Oncol, 2010, 11(1):21-28.
[7] Rodríguez MO, Rivero TC, del Castillo Bahi R, et al. Nimotuzumab plus radiotherapy for unresectable squamous-cell carcinoma of the head and neck[J]. Cancer Biol Ther, 2010, 9(5):343-349.
[8] Lu T, Zhao C, Chen C, et al. An open, multicenter clinical study on cetuximab combined with intensity modulated radiotherapy (IMRT) plus concurrent chemotherapy in nasopharyngeal carcinoma(NPC): preliminary report[J]. J Clin Oncol, 2010, 28(15):5577-5577.
[9] Cohen EE, Haraf DJ, Kunnavakkam R, et al. Epidermal growth factor receptor inhibitor gefitinib added to chemoradiotherapy in locally advanced head and neck cancer[J]. J Clin Oncol, 2010, 28(20):3336-3343.
[10] Herchenhorn D, Dias FL, Viegas CM, et al. Phase I/II study of erlotinib combined with cisplatin and radiotherapy in patients with locally advanced squamous cell carcinoma of the head and neck[J]. Int J Radiat Oncol Biol Phys, 2010, 78(3):696-702.
[11] Croci DO, Cerliani JP, Dalotto-Moreno T, et al. Glycosylation-dependent lectin-receptor interactions preserve angiogenesis in anti-VEGF refractory tumors[J]. Cell, 2014, 156(4):744-758.
[12] Carmeliet P, Jain RK. Molecular mechanisms and clinical applications of angiogenesis[J]. Nature, 2011, 473(7347): 298-307.
[13] Almangush A, Heikkinen I, Makitie AA, et al. Prognostic biomarkers for oral tongue squamous cell carcinoma: a systematic review and meta-analysis[J]. Br J Cancer, 2017, 117(6):856-866.
[14] Kuwahara Y, Mori M, Kitahara S, et al. Targeting of tumor endothelial cells combining 2 Gy/day of X-ray with Everolimus is the effective modality for overcoming clinically relevant radioresistant tumors[J]. Cancer Med, 2014, 3(2):310-321.
[15] Sato Y. Persistent vascular normalization as an alternative goal of anti-angiogenic cancer therapy[J]. Cancer Sci, 2011, 102(7): 1253-1256.
[16] Koontz BF, Miles EF, Rubio MA, et al. Preoperative radiotherapy and bevacizumab for angiosarcoma of the head and neck: two case studies[J]. Head Neck, 2008, 30(2):262-266.
[17] Argiris A, Karamouzis MV, Gooding WE, et al. Phase II trial of pemetrexed and bevacizumab in patients with recurrent or metastatic head and neck cancer[J]. J Clin Oncol, 2011, 29(9):1140-1145
[18] Li L, Liu RY, Huang JL, et al. Adenovirus-mediated intra-tumoral delivery of the human endostatin gene inhibits tumor growth in nasopharyngeal carcinoma[J]. Int J Cancer, 2006, 118(8):2064-2071.
[19] 秦叔逵, 李进. 阿帕提尼治疗胃癌的临床应用专家共识[J]. 临床肿瘤学杂志, 2015, 20(9):841-847.
[20] Haddad R, Colevas AD, Krane JF, et al. Herceptin in patients with advanced or metastatic salivary gland carcinomas. A phase II study[J]. Oral Oncol, 2003, 39(7):724-727.
[21] Ghosal N, Mais K, Shenjere P, et al. Phase II study of cisplatin and imatinib in advanced salivary adenoid cystic carcinoma[J]. Br J Oral Maxillofac Surg, 2011, 49(7):510-515.
[22] Chau NG, Hotte SJ, Chen EX, et al. A phase II study of sunitinib in recurrent and/or metastatic adenoid cystic carcinoma (ACC) of the salivary glands: current progress and challenges in evaluating molecularly targeted agents in ACC[J]. Ann Oncol, 2012, 23(6):1562-1570.
[23] Hrustanovic G, Lee BJ, Bivona TG. Mechanisms of resistance to EGFR targeted therapies[J]. Cancer Biol Ther, 2013, 14(4):304-314.
[24] Keysar SB, Le PN, Anderson RT, et al. Hedgehog signaling alters reliance on EGF receptor signaling and mediates anti-EGFR therapeutic resistance in head and neck cancer[J]. Cancer Res, 2013, 73(11):3381-3392.
[25] Calzone L, Kuperstein I, Cohen D, et al. Biological network modelling and precision medicine in oncology[J]. Bull Cancer, 2014, 101(Suppl 1):S18-S21.
[26] Papadatos-Pastos D, De Miguel Luken MJ, Yap TA. Combining targeted therapeutics in the era of precision medicine[J]. Br J Cancer, 2015, 112(1):1-3.
[27] Dy GK, Adjei AA. Understanding, recognizing, and managing toxicities of targeted anticancer therapies[J]. CA Cancer J Clin, 2013, 63(4):249-279.
[28] Ignatiadis M, Dawson SJ. Circulating tumor cells and circulating tumor DNA for precision medicine: dream or reality[J]. Ann Oncol, 2014, 25(12):2304-2313.
[29] Baksh K, Weber J. Immune checkpoint protein inhibition for cancer: preclinical justification for CTLA-4 and PD-1 blockade and new combinations[J]. Semin Oncol, 2015, 42(3):363-377.
[30] Turnis ME, Andrews LP, Vignali DA. Inhibitory receptors as targets for cancer immunotherapy[J]. Eur J Immunol, 2015, 45(7):1892-1905.
[1] 杨耀成,曾柳钧,钟良,鲜红春,张胜,吴汉江,朱兆夫. 上唇横纹肌肉瘤1例及文献复习[J]. 口腔颌面外科杂志, 2016, 26(2): 149-152.
[2] 李葵芳1,范德生2,刘晔1,范得泉3. 姜黄素对口腔鳞癌SCC-25细胞EGFR信号通路表达的影响[J]. 口腔颌面外科杂志, 2015, 25(5): 326-.
[3] 郭 伟, 宋 浩. 口腔颌面-头颈黏膜黑色素瘤的诊治现状和进展[J]. 口腔颌面外科杂志, 2015, 25(2): 85-.
[4] 王中和. 口腔颌面-头颈恶性肿瘤治疗的新策略:放疗联合个体化靶向治疗[J]. 口腔颌面外科杂志, 2014, 24(5): 325-.
[5] 李中连,邱芬芳,钱浩. 舌恶性黑色素瘤术后12年出现颈部转移1例[J]. 口腔颌面外科杂志, 2014, 24(5): 397-.
[6] 顾佳妹,苏俭生. 放射治疗对涎腺和成体干细胞的影响[J]. 口腔颌面外科杂志, 2012, 22(4): 292-295.
[7] 郭 伟. 晚期口腔颌面-头颈部鳞癌靶向治疗的进展浅析[J]. 口腔颌面外科杂志, 2012, 22(2): 77-81.
[8] 郭 伟. 晚期口腔颌面-头颈部鳞癌靶向治疗的进展浅析[J]. 口腔颌面外科杂志, 0, (): 77-81.
[9] 顾佳妹,苏俭生. 放射治疗对涎腺和成体干细胞的影响[J]. 口腔颌面外科杂志, 0, (): 292-295.
 

版权所有 © 《口腔颌面外科杂志》编辑部   沪ICP备14036353号-4

地址:上海延长中路399号   邮编:200072
本系统由北京玛格泰克科技发展有限公司设计开发 技术支持:support@magtech.com.cn